{"id":495475,"date":"2024-01-25T09:29:34","date_gmt":"2024-01-25T14:29:34","guid":{"rendered":"https:\/\/platohealth.ai\/another-step-toward-new-drugs-for-parkinsons\/"},"modified":"2024-01-25T13:18:47","modified_gmt":"2024-01-25T18:18:47","slug":"another-step-toward-new-drugs-for-parkinsons","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/another-step-toward-new-drugs-for-parkinsons\/","title":{"rendered":"Another step toward new drugs for Parkinson\u2019s","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"<div><img decoding=\"async\" src=\"https:\/\/platohealth.ai\/wp-content\/uploads\/2024\/01\/another-step-toward-new-drugs-for-parkinsons.jpg\" class=\"ff-og-image-inserted\"><\/div>\n<p><em>Want to stay on top of the science and politics driving biotech today?&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>&nbsp;to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Good morning, everyone. Damian here with the plight of the venture capitalist, an idea for Gilead Sciences, and the latest in the quest to find potent treatments for Parkinson\u2019s disease.<\/p>\n<div class=\"ad-in-article dfp-ad-midbreaker-wrap\">\n<p class=\"ad-label\">advertisement<\/p>\n<\/div>\n<h2>The need-to-know this morning<\/h2>\n<ul>\n<li>Cancer drug developer&nbsp;<strong>CG Oncology<\/strong>&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.businesswire.com\/news\/home\/20240124683185\/en\/CG-Oncology-Announces-Pricing-of-Upsized-Initial-Public-Offering?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\" data-hs-link-id=\"0\">raised $380 million<\/a>&nbsp;in an initial public offering. It\u2019s the first biotech IPO of 2024.<\/li>\n<\/ul>\n<h2>Biotech VCs are feeling the squeeze<\/h2>\n<p>As fledgling drug companies struggle to raise the cash they need to survive, spare a moment for the venture capitalists on the other side of the Zoom screen.<\/p>\n<p>As STAT\u2019s Allison DeAngelis&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/01\/25\/biotech-vcs-struggle-to-find-investors-is-slump-over?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\">reports<\/a>, biotech\u2019s lengthy downturn has put some VCs in uncomfortable positions as they try to raise new funds from the pensions, endowments, and other big-money organizations that supply their capital. Those funds have started making bolder requests, multiple VCs said, including pushing for more favorable terms and even asking for equity in the firm itself.<\/p>\n<p>\u201cI\u2019ve been at Sofinnova Partners for 26 years, and in the business for close to 30. This is the toughest it\u2019s been,\u201d said Antoine Papiernik, a managing partner at the firm. \u201cCaution is important for the next 12 months.\u201d<\/p>\n<div class=\"ad-in-article dfp-ad-midbreaker2-wrap\">\n<p class=\"ad-label\">advertisement<\/p>\n<\/div>\n<p><a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/01\/25\/biotech-vcs-struggle-to-find-investors-is-slump-over?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\">Read more<\/a>.<\/p>\n<h2>Gilead: Now what?<\/h2>\n<p>Gilead Sciences\u2019 dogged efforts to build a business in oncology have mostly amounted to disappointment, most recently with a clinical trial setback stemming from the company\u2019s $21 billion investment into antibody-drug conjugates.<\/p>\n<p>The shining exception is Gilead\u2019s acquisition of Kite Pharma, a pioneer in CAR-T therapy whose work has led to cornerstone treatments for certain cancers. So instead of throwing more money at disparate ideas in oncology that might only end in failure, why not double down on what works?<\/p>\n<p>As STAT\u2019s Adam Feuerstein&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/01\/25\/gilead-trodelvy-elevation-oncology-kura?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\">writes<\/a>, Gilead has a path forward in CAR-T through its partnership with Arcellx, a biotech company at work on what could become a best-in-class treatment for multiple myeloma. Buying Arcellx outright could help Gilead meet its goal of having oncology drugs contribute 30% of total product sales by 2030, a mark it\u2019s unlikely to hit on its own merits.<\/p>\n<p><a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/01\/25\/gilead-trodelvy-elevation-oncology-kura?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\">Read more<\/a>.<\/p>\n<h2>There\u2019s always money in obesity<\/h2>\n<p>If biotech is going to pull off the market turnaround so many in the industry have predicted for 2024, the sector is going to need more than a few companies to successfully go public. Last year, which saw just 11 biotech IPOs, doesn\u2019t exactly bode well. But there\u2019s good news: An obesity-related company might be waiting in the wings.<\/p>\n<p><a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.bloomberg.com\/news\/articles\/2024-01-23\/oral-weight-loss-drug-developer-kallyope-is-said-to-explore-ipo?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\" data-hs-link-id=\"0\">According to Bloomberg<\/a>, Kallyope is getting its paperwork together for an IPO, working with J.P. Morgan on an offering that could materialize this year. The company, founded in 2015, is&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/kallyope.com\/kallyope-enters-phase-2-with-first-in-class-oral-approach-for-the-treatment-of-both-obesity-and-type-2-diabetes-2\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\" data-hs-link-id=\"0\">developing oral treatments<\/a>&nbsp;designed to stimulate bodily hormones tied to satiety, working upstream of GLP-1 drugs like Wegovy.<\/p>\n<p>Treating obesity is among the vanishingly few things a biotech company can do to get attention from generalist investors in recent months, which means Kallyope\u2019s potential public debut could bring some much-needed capital back to the sector. Structure Therapeutics, a company with an oral GLP-1 treatment, was among 2023\u2019s only successful biotech IPOs.<\/p>\n<h2>Another step toward new drugs for Parkinson\u2019s<\/h2>\n<p>Building off of some landmark discoveries published last year, researchers have mapped out the biological underpinnings of Parkinson\u2019s disease, creating a framework for medicines that might treat the root of the disease rather than just its symptoms.<\/p>\n<p>Their work,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422(23)00404-0\/fulltext?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\" data-hs-link-id=\"0\">published in the Lancet Neurology<\/a>, stages Parkinson\u2019s based on the accumulation of a misfolded protein called alpha-synuclein. Funded by the Michael J. Fox Foundation for Parkinson\u2019s Research, the work&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2023\/04\/12\/michael-j-fox-parkinsons-biomarker\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\">expands on a 2023 publication<\/a>&nbsp;that validated an alpha-synuclein diagnostic for the disease.<\/p>\n<p>The new framework still has some gaps, but the researchers believe they\u2019ve set out a path that will allow scientists to discover and rigorously test treatments aimed at the biological causes of Parkinson\u2019s, providing a reliable measure of disease severity that might accelerate the process of drug development.<\/p>\n<h2>More reads<\/h2>\n<ul>\n<li>When it comes to policing pharma, the FTC says it\u2019s on \u2018an incredible winning streak,\u2019&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/pharmalot\/2024\/01\/24\/ftc-biden-patents-rebates-pbm-mergers-sanofi-gsk-astrazeneca-amgen\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\">STAT<\/a><\/li>\n<li>British billionaire Joe Lewis pleads guilty to biotech insider trading,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.cnbc.com\/2024\/01\/24\/british-billionaire-joe-lewis-pleads-guilty-to-insider-trading.html?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\" data-hs-link-id=\"0\">CNBC<\/a><\/li>\n<li>Select A PBM in Africa flips the industry\u2019s script in a bid to make people healthier,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/01\/25\/maisha-meds-pbm\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\">STAT<\/a><\/li>\n<li>Lilly\u2019s Mounjaro dose in limited availability in US through next month,&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/lillys-mounjaro-dose-limited-availability-us-through-next-month-2024-01-24\/?utm_campaign=the_readout&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--XbGHYwlRr5OZdrTomHbTe4lpGVTwLgrq_GkCu9h7cCIRFOG2Cia-joy4xARBUYVW9fJ4C\" data-hs-link-id=\"0\">Reuters<\/a><\/li>\n<\/ul>\n<p><em>Pssst. If you\u2019ve made it to the end of this article, you might be interested in joining this&nbsp;<a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/scorecard\/\">secret list<\/a> for an upcoming biotech newsletter. Just some food for thought.<\/em><\/p>\n<ul class=\"plato-post-bottom-links\">\n<li class=\"plato-post-bottom-link-amplifi\">SEO Powered Content &amp; PR Distribution. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.amplifipr.com\">Get Amplified Today.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platodata-network\">PlatoData.Network Vertical Generative Ai. Empower Yourself. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platodata.network\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoaistream\">PlatoAiStream. Web3 Intelligence. Knowledge Amplified. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoaistream.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoesg\">PlatoESG. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/carbon\/\">Carbon,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/cleantech\/\">CleanTech,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/energy\/\">Energy,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/environment\/\">Environment,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/solar\/\">Solar,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/waste-management\/\">Waste Management.<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platohealth\">PlatoHealth. Biotech and Clinical Trials Intelligence. <a href=\"https:\/\/platohealth.ai\" target=\"_blank\" rel=\"noopener\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-source\"><span>Source:<\/span> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.statnews.com\/2024\/01\/25\/biotech-news-parkinsons-gilead-cg-oncologly-kallyope-mounjaro-glp-1-car-t-arcellx\/?utm_campaign=rss\">https:\/\/www.statnews.com\/2024\/01\/25\/biotech-news-parkinsons-gilead-cg-oncologly-kallyope-mounjaro-glp-1-car-t-arcellx\/?utm_campaign=rss<\/a><\/li>\n<\/ul>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"<p>Want to stay on top of the science and politics driving biotech today?&nbsp;Sign up&nbsp;to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the plight of the venture capitalist, an idea for Gilead Sciences, and the latest in the quest to find potent treatments for Parkinson\u2019s disease. advertisement The need-to-know this [&hellip;]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":495478,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/495475"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=495475"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/495475\/revisions"}],"predecessor-version":[{"id":495477,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/495475\/revisions\/495477"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/495478"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=495475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=495475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=495475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}